Carbazochrome is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone [4]. In the future this may prevent excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on effectiveness and severity of side effects remains inconclusive. It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.

Carbazochrome has been investigated for use in the treatment of non-surgical acute uncomplicated hemorrhoids in a mixture with [DB13124], and this combination therapy demonstrated efficacy and safe tolerability either at a local or systemic level [1].



Indicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura.


Carbazochrome is an anti-bleeding agent that increases platelet aggregation and forms a platelet plug by interacting with α-adrenoreceptors on surface of platelets [ Read more

Mechanism of action

Carbazochrome interacts with platelet surface α-adrenoreceptors which are Gq-coupled receptors that leads to activation of PLC IP3/DAG pathway and increase in intracellular calcium levels. Elevated calcium ions bind to calmodulin and activates Ca2+/calmodulin-dependent myosin light chain kinase, all... Read more


Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.


Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.


Information currently not available.

Adverse Effects


Information currently not available.

Food Interactions

    Information currently not available.


Type in a drug name to check for interaction with Carbazochrome
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
5 References
  1. 1 . Squadrito F, Altavilla D, Oliaro Bosso S: Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids. Eur Rev Med Pharmacol Sci. 2000 Jan-Apr;4(1-2):21-4.PubMed: 11409185
  2. 2 . Sendo T, Itoh Y, Aki K, Oka M, Oishi R: Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):175-80. Epub 2003 Aug 20.PubMed: 12928765
  3. 3 . Sendo T, Goromaru T, Aki K, Sakai N, Itoh Y, Oishi R: Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. Eur J Pharmacol. 2002 Aug 23;450(2):203-8.PubMed: 12206859
  4. 4 . Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro GS: Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study. Curr Med Res Opin. 2001;17(4):256-61.PubMed: 11922398
  5. 5 . Ghareeb H, Karaman R. (2015). 6. In Commonly Used Drugs: Uses, Side Effects, Bioavailability and Approaches to Improve It (1st ed., pp. 210). Nova Science Pub Inc; UK ed. edition.